Promising Pathway Act 2.0

The Promising Pathway Act 2.0 creates a new FDA pathway for conditional approval of drugs treating rare, progressive, and serious diseases. This allows patients with limited treatment options to access promising new drugs sooner, based on preliminary safety data from Phase 1 trials and effectiveness data from Phase 2 trials (or preliminary evidence for terminal pediatric rare diseases). The law requires drug sponsors to establish observational registries tracking patient outcomes, mandates specific labeling for conditionally approved drugs, and requires private health insurers and federal health care programs to cover these drugs without cost-sharing. Conditional approval is initially granted for 2 years with potential for up to 3 renewals (totaling 8 years), but can be withdrawn if safety data changes or sponsors fail to meet requirements.